Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 26:3:695.
doi: 10.1186/2193-1801-3-695. eCollection 2014.

Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance

Affiliations
Review

Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance

Ram Kumar Sahu et al. Springerplus. .

Abstract

Pharmacovigilance plays a consequential role in the surveillance of adverse drug reactions, which is provoked by the drugs used to cure diseases. Adverse drug reactions (ADRs) produce detrimental or undesirable effects to the body after administration of drugs. It has been reported that the number of patients dying because of contrary effects of drugs per year increased upto 2.6-fold. Moreover, rates of hospitalization of patients are increasing owing to adverse effects of drugs. Thus, it becomes challengeable for physician, health care providers, WHO and pharmaceutical industries to resolve the associated problem of ADRs. During the clinical trial of a novel drug, it is prominent to explore the dependability of drug. In this review, we documented the details required to identify the ADRs in patients along with reported banned drugs.

Keywords: Adverse drug reactions; Clinical trial; Pharmacovigilance.

PubMed Disclaimer

References

    1. Aeries N. Consumer reporting of ADRs. WHO Drug Information. 1995;14:211–215.
    1. Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M. What can we learn from parents about enhancing participation in Pharmacovigilance? British J Clin Pharmacol. 2012;78(2):312–322. - PMC - PubMed
    1. Arora D. Pharmacovigilance obligations of the pharmaceutical companies in India. Indian J Pharmacol. 2008;40:13–16. - PMC - PubMed
    1. Bahri P, Tsintis P. Pharmacovigilance–related topics at the level of the International Conference on Harmonisation (ICH) Pharmacoepidemiol Drug Saf. 2005;14:377–387. doi: 10.1002/pds.1043. - DOI - PubMed
    1. Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274:29–34. doi: 10.1001/jama.1995.03530010043033. - DOI - PubMed

LinkOut - more resources